Bajwa HK, Singareddy R, Reddy MM, Raju KA, Rao ST, Rajappa SJ (2018) Preoperative chemoradiation in carcinoma esophagus: Experience from a tertiary cancer center in India. Indian J Med Paediatr Oncol 39:272–275. https://doi.org/10.4103/ijmpo.ijmpo_16_16

Article  Google Scholar 

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71(3):209–249. https://doi.org/10.3322/caac.21660

Article  CAS  PubMed  Google Scholar 

Grille VJ, Campbell S, Gibbs JF, Bauer TL (2021) Esophageal cancer: The rise of adenocarcinoma over squamous cell carcinoma in the Asian belt. J Gastrointest Oncol 12:S339–S349. https://doi.org/10.21037/JGO-2019-GI-08

Article  PubMed  PubMed Central  Google Scholar 

Nachiappan M, Kapoor VK (2022) Esophageal Cancer: Whether and What Before or After Surgery? Indian J Surg Oncol 13:880–887. https://doi.org/10.1007/s13193-022-01655-y

Article  PubMed  PubMed Central  Google Scholar 

Gebski V, Burmeister B, Mark Smithers B, Foo K, Zalcberg J (2007) Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis 8. https://doi.org/10.1016/S1470

Eyck BM, van Lanschot JJB, Hulshof MCCM, van der Wilk BJ, Shapiro J, van Hagen P et al (2021) Ten-Year Outcome of Neoadjuvant Chemoradiotherapy Plus Surgery for Esophageal Cancer: The Randomized Controlled CROSS Trial. J Clin Oncol 39:1995–2004. https://doi.org/10.1200/JCO.20.03614

Article  CAS  PubMed  Google Scholar 

Kumar T, Pai E, Singh R, Francis NJ, Pandey M (2020) Neoadjuvant strategies in resectable carcinoma esophagus: a meta-analysis of randomized trials. World J Surg Oncol 18:59. https://doi.org/10.1186/s12957-020-01830-x

Article  PubMed  PubMed Central  Google Scholar 

Noordman BJ, Verdam MGE, Lagarde SM, Hulshof MCCM, van Hagen P, van Berge Henegouwen MI et al (2017) Effect of Neoadjuvant Chemoradiotherapy on Health-Related Quality of Life in Esophageal or Junctional Cancer: Results From the Randomized CROSS Trial. J Clin Oncol 36:268–275. https://doi.org/10.1200/JCO.2017.73.7718

Article  PubMed  Google Scholar 

Hoeppner J, Lordick F, Brunner T, Glatz T, Bronsert P, Röthling N et al (2016) ESOPEC: Prospective randomized controlled multicenter phase III trial comparing perioperative chemotherapy (FLOT protocol) to neoadjuvant chemoradiation (CROSS protocol) in patients with adenocarcinoma of the esophagus (NCT02509286). BMC Cancer 16:2509286. https://doi.org/10.1186/s12885-016-2564-y

Article  CAS  Google Scholar 

Haque W, Butler EB, Teh BS (2019) Neoadjuvant radiation therapy for esophageal cancer: Is a higher dose better? J Thorac Dis 11:5631–5634. https://doi.org/10.21037/jtd.2019.11.77

Article  PubMed  PubMed Central  Google Scholar 

Montagnani F, Fornaro L, Frumento P, Vivaldi C, Falcone A, Fioretto L (2017) Multimodality treatment of locally advanced squamous cell carcinoma of the oesophagus: A comprehensive review and network meta-analysis. Crit Rev Oncol Hematol 114:24–32. https://doi.org/10.1016/j.critrevonc.2017.03.024

Article  PubMed  Google Scholar 

Sjoquist KM, Burmeister BH, Smithers BM, Zalcberg JR, Simes RJ, Barbour A et al (2011) Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. Lancet Oncol 12:681–692. https://doi.org/10.1016/S1470-2045(11)70142-5

Article  PubMed  Google Scholar 

Pasquali S, Yim G, Vohra RS, Mocellin S, Nyanhongo D, Marriott P et al (2017) Survival after neoadjuvant and adjuvant treatments compared to surgery alone for resectable esophageal carcinoma: a network meta-analysis. Ann Surg 265(3):481–491. https://doi.org/10.1097/SLA.0000000000001905

Appius H, Hafer J, Harms W, Bolli M, Buess M (2023) Reproducibility of the CROSS trial results in the multimodal treatment of esophageal cancer in daily practice: a single center retrospective observational study. J Oncol. 2023. https://doi.org/10.1155/2023/8955720

Krishnamurthy A, Mohanraj N, Radhakrishnan V, John A, Selvaluxmy G (2017) Neoadjuvant chemoradiation for locally advanced resectable carcinoma of the esophagus: A single-center experience from India with a brief review of the literature. Indian J Cancer 54:646–651. https://doi.org/10.4103/ijc.IJC_452_17

Article  PubMed  Google Scholar 

Nath J, Nath J, Kalita AK, Bhattacharyya M, Yanthan Y, Das J (2024) Debating the Optimal Preoperative Approach: NACRT vs NACT in Locally Advanced Oesophageal Cancer. Indian J Surg Oncol 15:573–580. https://doi.org/10.1007/s13193-024-02073-y

Article  PubMed  PubMed Central  Google Scholar 

Viswanathan MP, Suresh Kumar D, Arul Kumar G, Sakthi Usha Devi J, Balamurugan TD (2020) Analysis of Carcinoma of the Esophagus Patients Between Upfront Surgery vs. Neoadjuvant Therapy Followed by Surgery. Indian J Surg 82:1026–1030. https://doi.org/10.1007/s12262-020-02156-4

Article  Google Scholar 

Van Hagen P, Hulshof MCCM, Van Lanschot JJB, Steyerberg EW, Van Berge Henegouwen MI, Wijnhoven BPL et al (2012) Preoperative chemoradiotherapy for esophageal or junctional cancer

Saeki H, Morita M, Nakashima Y, Sonoda H, Hashimoto K, Egashira A et al (2011) Neoadjuvant chemoradiotherapy for clinical stage II-III esophageal squamous cell carcinoma. Anticancer Res 31(9):3073–3077

Horne ZD, Wegner RE, Colonias A, Weksler B, Glaser SM, Kalash R et al (2020) Drivers of 30- and 90-day Postoperative Death After Neoadjuvant Chemoradiation for Esophageal Cancer. Ann Thorac Surg 109:921–926. https://doi.org/10.1016/j.athoracsur.2019.10.057

Article  PubMed  Google Scholar 

Bhattacharyya T, Arunsingh M, Chakraborty S, Harilal V, Sasidharan R, Saha S et al (2021) Can the cross protocol be safely implemented in real world scenario with broader eligibility criteria? experience from a tertiary care Centre in India. Ecancermedicalscience 15. https://doi.org/10.3332/ecancer.2021.1291

Mariette C, Taillier G, Van Seuningen I, Triboulet J-P (2004) Factors Affecting Postoperative Course and Survival After En Bloc Resection for Esophageal Carcinoma. Ann Thorac Surg 78:1177–1183. https://doi.org/10.1016/j.athoracsur.2004.02.068

Article  PubMed  Google Scholar 

Das G, Arun PS, Roy PS, Sarma G, Nath J, Kalita DJ et al (2024) Real-World Experience of Patient’s Compliance and Clinical Outcomes for Trimodality Treatment for Esophageal Cancer: a Study from a Cancer Center in North-East India. Indian J Surg Oncol 15:241–249. https://doi.org/10.1007/s13193-024-01881-6

Article  PubMed  PubMed Central  Google Scholar 

Chi CL, Gao X, Hsieh HY, Cheng YH, Yang ZH, Chao YK (2023) Survival outcomes of patients with esophageal cancer who did not proceed to surgery after neoadjuvant treatment. Cancers (Basel) 15. https://doi.org/10.3390/cancers15164049

Depypere L, Thomas M, Moons J, Coosemans W, Lerut T, Prenen H et al (2019) Analysis of patients scheduled for neoadjuvant therapy followed by surgery for esophageal cancer, who never made it to esophagectomy. World J Surg Oncol 17. https://doi.org/10.1186/s12957-019-1630-8

Harris C, Debnath S, Jagtap V, Lynser D, Raphael V (2025) Compliance to Multimodality Treatment for Oesophageal Cancer at a High Incidence Region of India. Indian J Surg Oncol. https://doi.org/10.1007/s13193-025-02368-8

Article  PubMed  PubMed Central  Google Scholar 

Van Meerten E, Muller K, Tilanus HW, Siersema PD, Eijkenboom WMH, Van Dekken H et al (2006) Neoadjuvant concurrent chemoradiation with weekly paclitaxel and carboplatin for patients with oesophageal cancer: A phase II study. Br J Cancer 94:1389–1394. https://doi.org/10.1038/sj.bjc.6603134

Article  CAS  PubMed  PubMed Central  Google Scholar 

Van Westreenen HL, Westerterp M, Bossuyt PMM, Pruim J, Sloof GW, van Lanschot JJB et al (2025) Systematic Review of the Staging Performance of 18F-Fluorodeoxyglucose Positron Emission Tomography in Esophageal Cancer. J Clin Oncol 22:3805–3812. https://doi.org/10.1200/JCO.2004.01.083

Article  Google Scholar 

Ohkura Y, Shindoh J, Ueno M, Iizuka T, Udagawa H (2018) Comparison of Outcome of Esophagectomy Versus Nonsurgical Treatment for Resectable Esophageal Cancer with Clinical Complete Response to Neoadjuvant Therapy. Ann Surg Oncol 25:2428–2433. https://doi.org/10.1245/s10434-018-6437-2

Article  PubMed  Google Scholar 

Guinan E, Dowds J, Donohoe C, Reynolds J, Hussey J (2016) The physiotherapist and the esophageal cancer patient: from prehabilitation to rehabilitation: Physiotherapy and esophageal cancer. Dis Esophagus 30. https://doi.org/10.1111/dote.12514